Auf dieser Seite
01AORT Preis
02Momentaufnahme
03Chart
04Aktiensplits
05Über uns
06Performance
07Bewertung & Kennzahlen
13Dividenden
14Erträge
15Vollständige Fundamentaldaten
16Erklärungen
17Institutionelle Eigentümer (13F)
18Aktivisten & 5%+-Eigentümer
19Unternehmensinsider
20ETF-Besitz
21Konsens
22Peers
23Nachrichten
26Meine Kennzahlen
AORT Artivion, Inc. Common Stock
NYSE · Health Care · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 7, 2026
$22,31
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$19,1652-Wochen-Tief
$48,2552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.12B
P/E (TTM)
-371.8
EPS (TTM)
$-0.06
Umsatz (TTM)
$471M
Ihre Abzeichen
52W-Spanne
$19–$48
Analystenbewertung
BUY
Kursziel
$42
P/E
-371.8
ROE
-0.73%
Nettogewinnmarge
-0.67%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
AORT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$22.31
Marktkapitalisierung (MRQ)
$1.12B
P/E (TTM)
-371.8
EPS (TTM)
$-0.06
Umsatz (TTM)
$471M
ROE (TTM)
-0.73%
Verschuldungsgrad (MRQ)
0.8
52W-Spanne
$19–$48
AORT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 28. Dezember 2000 | 3-for-2 | Vorwärts |
| 1. Juli 1996 | 2-for-1 | Vorwärts |
Über Artivion, Inc. Common Stock Unternehmensübersicht von Wikipedia
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
## History
Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally. Anderson acted as the company’s president and CEO from its founding. The company later moved from Sarasota to the Atlanta metropolitan area. In January 2022 the company changed its name to Artivion, Inc.
In 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries.
In February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue. In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had less of a chance of rejection than previous valves.
In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery.
In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.
In October 2017, Artivion acquired JOTEC GmbH, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million. In September 2020, the company acquired Ascyrus Medical.
In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system, which comprised PerClot granules and a delivery system for surgical use. Baxter International agreed to buy PerClot from Artivion in 2021. In 2023, after final FDA approval of the product, the purchase was completed.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealth Care
BrancheHealth Care
Mitarbeiter1.800
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$441M2016-12-31 → 2025-12-31
EPS$0.212016-12-31 → 2025-12-31
Freier Cashflow$839.0K2016-12-31 → 2025-12-31
Nettogewinnmarge-0.67%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | AORT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -371.85-Jahres-Durchschnitt ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.45-Jahres-Durchschnitt ≈3.0 | ≈3.0 | 3.9 | Unterbewertet | |
| K/B (MRQ) | 2.55-Jahres-Durchschnitt ≈3.4 | ≈3.4 | 3.9 | Unterbewertet | |
| EV / EBITDA | 22.55-Jahres-Durchschnitt ≈32.6 | ≈32.6 | · | · | |
| Kurs / FCF (TTM) | -122.35-Jahres-Durchschnitt ≈554.3 | ≈554.3 | · | · | |
| Kurs / Cashflow (TTM) | 26.85-Jahres-Durchschnitt ≈-54.3 | ≈-54.3 | 38.0 | Überbewertet | |
| EV / Revenue (EV / Umsatz) | 2.95-Jahres-Durchschnitt ≈3.7 | ≈3.7 | · | · | |
| EV / FCF | 1508.15-Jahres-Durchschnitt ≈592.1 | ≈592.1 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 3.8 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | AORT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 64.4%5-Jahres-Durchschnitt ≈64.8% | ≈64.8% | 64.0% | Im Einklang | |
| Betriebsgewinnmarge (TTM) | 4.4%5-Jahres-Durchschnitt ≈4.8% | ≈4.8% | -7.6% | Im Einklang | |
| EBITDA-Marge (TTM) | 9.6%5-Jahres-Durchschnitt ≈11.4% | ≈11.4% | -7.6% | Im Einklang | |
| Vorgewinnmarge (TTM) | 0.47%5-Jahres-Durchschnitt ≈-2.9% | ≈-2.9% | -8.7% | Im Einklang | |
| Nettogewinnmarge (TTM) | -0.67%5-Jahres-Durchschnitt ≈-4.2% | ≈-4.2% | -9.5% | Im Einklang | |
| ROA (TTM) | -0.33%5-Jahres-Durchschnitt ≈-1.8% | ≈-1.8% | -20.2% | Spitzenklasse | |
| ROE (TTM) | -0.73%5-Jahres-Durchschnitt ≈-5.1% | ≈-5.1% | -25.1% | Spitzenklasse | |
| ROIC | 3.4%5-Jahres-Durchschnitt ≈3.8% | ≈3.8% | -31.3% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | AORT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.85-Jahres-Durchschnitt ≈1.0 | ≈1.0 | 0.6 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 3.55-Jahres-Durchschnitt ≈4.6 | ≈4.6 | 5.6 | Geringe Liquidität | |
| Quick Ratio | 1.55-Jahres-Durchschnitt ≈2.0 | ≈2.0 | 3.6 | Geringe Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.85-Jahres-Durchschnitt ≈1.0 | ≈1.0 | 0.6 | Hohe Verschuldung |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | AORT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 13.6%5-Jahres-Durchschnitt ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 12.0%5-Jahres-Durchschnitt ≈11.0% | ≈11.0% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 11.8% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | AORT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.55-Jahres-Durchschnitt ≈0.5 | ≈0.5 | 0.5 | Im Einklang | |
| Inventory Turnover (Lagerumschlag) | 1.85-Jahres-Durchschnitt ≈1.6 | ≈1.6 | 1.8 | Im Einklang | |
| Receivables Turnover (Forderungsumschlag) | 5.25-Jahres-Durchschnitt ≈5.4 | ≈5.4 | 6.9 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$245.2K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Annualisierte Auszahlung≈$0.12
| Ex-Datum | Betrag | Währung | Rendite |
|---|---|---|---|
| Dez 9, 2015 | $0,03 | USD | ≈1.2% |
| Sep 9, 2015 | $0,03 | USD | ≈1.2% |
| Jun 10, 2015 | $0,03 | USD | ≈1.1% |
| Mär 11, 2015 | $0,03 | USD | ≈1.2% |
| Dez 10, 2014 | $0,03 | USD | ≈1.1% |
| Sep 10, 2014 | $0,03 | USD | ≈1.2% |
| Jun 11, 2014 | $0,03 | USD | ≈1.3% |
| Mär 12, 2014 | $0,03 | USD | ≈1.2% |
| Dez 11, 2013 | $0,03 | USD | ≈1.1% |
| Sep 11, 2013 | $0,03 | USD | ≈1.7% |
| Jun 12, 2013 | $0,03 | USD | ≈1.7% |
| Mär 12, 2013 | $0,03 | USD | ≈1.2% |
| Dez 12, 2012 | $0,03 | USD | ≈0.83% |
| Sep 12, 2012 | $0,03 | USD | ≈0.45% |
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-518.1%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 5, 2026 | $-0.28 | $0.01 | -2845.1% |
| 31. März 2026 | $0.03 | $0.05 | -40.1% | |
| 31. Dezember 2025 | $0.05 | $0.08 | -40.0% | |
| 30. September 2025 | $0.06 | $0.02 | 242.9% | |
| 30. Juni 2025 | $0.08 | $-0.00 | — | |
| 31. März 2025 | $-0.01 | $-0.12 | 91.7% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Cost of Revenue | $157M | $140M | $125M | $111M | $101M | $85M | $93M | $90M | $61M | $61M | $55M | $53M | |
| Gross Profit | $284M | $249M | $229M | $203M | $198M | $168M | $183M | $173M | $129M | $119M | $91M | $91M | |
| R&D Expense | $31M | $28M | $29M | $39M | $36M | $24M | $23M | $23M | $19M | $13M | $10M | $9M | |
| SG&A Expense | $226M | $181M | $209M | $157M | $170M | $141M | $143M | $141M | $101M | $92M | $75M | $74M | |
| Operating Expenses | $257M | $210M | $238M | $196M | $205M | $165M | $166M | $164M | $121M | $105M | $85M | $82M | |
| Operating Income | $34M | $39M | $6M | $6M | $8M | $2M | $17M | $9M | $8M | $22M | $5M | $9M | |
| Interest Expense | · | · | $25M | $18M | $17M | $17M | $15M | $16M | $5M | $3M | $62.0K | $175.0K | |
| Interest Income | $763.0K | $1M | $1M | $147.0K | $79.0K | $217.0K | $738.0K | $226.0K | $212.0K | $72.0K | $45.0K | $50.0K | |
| Other Non-op | $10M | $-10M | $-3M | $-3M | $-6M | $-3M | $-1M | $-141.0K | $260.0K | $-437.0K | $-484.0K | $-540.0K | |
| Pretax Income | $15M | $-8M | $-22M | $-15M | $-15M | $-17M | $2M | $-6M | $4M | $18M | $6M | $9M | |
| Income Tax | $5M | $6M | $9M | $4M | $7.0K | $-492.0K | $-76.0K | $-4M | $-143.0K | $8M | $2M | $1M | |
| Net Income | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| EPS (Basic) | $0.22 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.33 | $0.14 | $0.26 | |
| EPS (Diluted) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 | |
| Shares (Basic) | 45,335,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,118,000 | 36,412,000 | 33,008,000 | 31,855,000 | 27,744,000 | 27,379,000 | |
| Shares (Diluted) | 47,162,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,860,000 | 36,412,000 | 34,163,000 | 32,822,000 | 28,542,000 | 28,313,000 | |
| EBITDA | $56M | $63M | $29M | $29M | $32M | $23M | $35M | $27M | $18M | $30M | · | $15M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65M | $53M | $59M | $39M | $55M | $61M | $34M | $41M | $40M | $57M | $38M | $33M | |
| Receivables | $90M | $79M | $72M | $62M | $53M | $46M | $53M | $47M | $48M | $28M | $23M | $21M | |
| Inventory | $92M | $80M | $82M | $74M | $77M | $73M | $53M | $45M | $47M | $26M | $15M | $13M | |
| Prepaid Expense | $43M | $19M | $16M | $18M | $15M | $14M | $12M | $7M | $5M | $3M | $5M | $5M | |
| Current Assets | $358M | $290M | $281M | $247M | $248M | $235M | $187M | $179M | $179M | $147M | $110M | $106M | |
| PP&E (Net) | $65M | $36M | $38M | $39M | $38M | $33M | $32M | $31M | $34M | $19M | $11M | $12M | |
| PP&E (Gross) | · | · | · | $127M | $120M | $111M | $103M | $96M | $93M | $74M | $64M | $62M | |
| Accum. Depreciation | · | · | · | $88M | $82M | $78M | $71M | $65M | $60M | $55M | $53M | $50M | |
| Goodwill | $254M | $241M | $247M | $244M | $250M | $260M | $187M | $189M | $188M | $78M | $11M | $11M | |
| Intangibles | $124M | $128M | $143M | $151M | $167M | $186M | $115M | $118M | $130M | $1M | $1M | $2M | |
| Other Non-current Assets | $15M | $24M | $9M | $7M | $8M | $15M | $14M | $8M | $7M | $2M | $6M | $5M | |
| Total Assets | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Accounts Payable | $16M | $18M | $13M | $12M | $10M | $10M | $10M | $8M | $10M | $6M | $5M | $4M | |
| Accrued Liabilities | $16M | $12M | $10M | $12M | $8M | $7M | $7M | $7M | $12M | $5M | $3M | $3M | |
| Current Liabilities | $102M | $67M | $58M | $50M | $45M | $60M | $45M | $35M | $43M | $30M | $20M | $21M | |
| Capital Leases | $34M | $40M | $44M | $41M | $45M | $14M | $18M | $0 | $7M | $11.0K | · | · | |
| Deferred Tax | $24M | $20M | $22M | $24M | $29M | $35M | $26M | $27M | $30M | $7.0K | · | · | |
| Other Non-current Liabilities | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $7M | $8M | $5M | $3M | $3M | |
| Total Liabilities | $437M | $513M | $511M | $478M | $492M | $461M | $320M | $296M | $313M | $107M | $26M | $27M | |
| Long-term Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Total Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Common Stock | $493.0K | $434.0K | $426.0K | $418.0K | $414.0K | $404.0K | $390.0K | $385.0K | $376.0K | $342.0K | $298.0K | $292.0K | |
| Retained Earnings | $-51M | $-61M | $-48M | $-17M | $2M | $20M | $37M | $35M | $38M | $34M | $23M | $23M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $13M | $12M | $11M | $9M | |
| AOCI | $-3M | $-25M | $-12M | $-22M | $-10M | $7M | $-9M | $-6M | $2M | $-429.0K | $-76.0K | $-121.0K | |
| Stockholders' Equity | $448M | $276M | $282M | $284M | $301M | $329M | $286M | $275M | $277M | $209M | $155M | $149M | |
| Liabilities + Equity | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Shares Outstanding | 49,330,000 | 43,432,000 | 42,569,000 | 41,830,000 | 41,397,000 | 40,394,000 | 39,018,000 | 38,463,000 | 37,618,000 | 34,230,000 | 29,766,000 | 29,229,000 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $22M | $24M | $23M | $22M | $24M | $21M | $18M | $18M | $10M | $8M | $6M | $6M | |
| Stock-based Comp | $24M | $14M | $14M | $12M | $11M | $7M | $9M | $6M | $7M | $6M | $5M | $3M | |
| Deferred Tax | $37.0K | $-2M | $-1M | $-885.0K | $-6M | $816.0K | $-2M | $-6M | $-1M | $3M | $1M | $173.0K | |
| Amort. of Intangibles | $14M | $16M | $15M | $15M | $17M | $14M | $11M | $11M | $5M | $4M | $2M | $2M | |
| Other Non-cash | $-17M | $-1M | $13M | $-20M | $-17M | $611.0K | $-11M | $-5M | $-8M | $-8M | · | $-9M | |
| Operating Cash Flow | $40M | $22M | $19M | $-5M | $-3M | $12M | $16M | $10M | $11M | $20M | $11M | $8M | |
| CapEx | $39M | $11M | $10M | $11M | $13M | $7M | $8M | $6M | $7M | $6M | $3M | $4M | |
| Investing Cash Flow | $-42M | $-28M | $-502.0K | $-11M | $6M | $-73M | $-24M | $-7M | $-171M | $-79M | $-4M | · | |
| Debt Issued | $0 | $184M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $-210.0K | $-28M | $-3M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | $2M | $3M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $6M | |
| Net Stock Activity | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | · | $-3M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $3M | $3M | |
| Financing Cash Flow | $11M | $2M | $865.0K | $-2M | $-12M | $94M | $-1M | $-3M | $143M | $73M | $-3M | · | |
| Net Change in Cash | $11M | $-5M | $20M | $-16M | $-7M | $28M | $-8M | $1M | $-17M | $14M | $4M | $-4M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | $145.0K | $3M | |
| Free Cash Flow | $839.0K | $11M | $11M | $-14M | $-16M | $5M | $8M | $4M | $4M | $14M | · | $4M | |
| Levered FCF | · | · | $-25M | $-38M | $-33M | $-11M | $-8M | $-3M | $-925.8K | $12M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% | 66.3% | 66.3% | 65.8% | 67.8% | 65.9% | · | 63.1% | |
| Operating Margin | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% | 0.96% | 6.2% | 3.5% | 4.2% | 12.1% | · | 6.1% | |
| Net Margin | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% | 0.62% | -1.1% | 1.9% | 6.0% | · | 5.1% | |
| Pretax Margin | 3.4% | -1.9% | -6.1% | -4.8% | -5.0% | -6.8% | 0.60% | -2.4% | 1.9% | 10.2% | · | 6.0% | |
| EBITDA Margin | 12.7% | 16.2% | 8.1% | 9.1% | 10.7% | 9.1% | 12.8% | 10.4% | 9.3% | 16.7% | · | 10.3% | |
| ROA | 1.2% | -1.7% | -4.0% | -2.5% | -1.9% | -2.4% | 0.29% | -0.49% | 0.82% | 4.3% | · | 4.2% | |
| ROE | 2.2% | -4.6% | -11.1% | -7.1% | -4.9% | -5.1% | 0.61% | -1.0% | 1.5% | 5.9% | · | 5.0% | |
| ROIC | 3.4% | 11.7% | 1.4% | 1.3% | 1.3% | 0.38% | 3.6% | 0.84% | 1.7% | 4.5% | · | 5.0% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 | 3.9 | 4.1 | 5.2 | 4.2 | 4.9 | · | 5.1 | |
| Quick Ratio | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 | 1.8 | 1.9 | 2.6 | 2.0 | 2.8 | · | 2.6 | |
| Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| LT Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| Interest Coverage | · | · | 0.2 | 0.3 | 0.5 | 0.1 | 1.1 | 0.6 | 1.6 | 7.3 | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.4 | 0.7 | · | 0.8 | |
| Inventory Turnover | 1.8 | 1.7 | 1.6 | 1.5 | 1.4 | 1.4 | 1.9 | 1.9 | 1.7 | 3.0 | · | 4.7 | |
| Receivables Turnover | 5.2 | 5.1 | 5.3 | 5.5 | 6.0 | 5.1 | 5.5 | 5.6 | 5.0 | 7.0 | · | 7.4 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $9.09 | $6.36 | $6.62 | $6.80 | $7.26 | $8.14 | $7.32 | $7.15 | $7.37 | $6.11 | · | $5.09 | |
| Revenue / Share | $9.36 | $9.32 | $8.69 | $7.84 | $7.67 | $6.69 | $7.30 | $7.22 | $5.55 | $5.50 | · | $5.11 | |
| Cash Flow / Share | $0.85 | $0.53 | $0.46 | $-0.13 | $-0.07 | $0.33 | $0.42 | $0.27 | $0.32 | $0.60 | · | $0.29 | |
| Cash / Share | $1.32 | $1.23 | $1.38 | $0.94 | $1.33 | $1.52 | $0.87 | $1.08 | $1.06 | $1.65 | · | $1.14 | |
| Dividend / Share | · | · | · | · | · | · | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.12 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | · | · | $0.12 | $0.12 | |
| EPS (TTM) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 13.6% | 9.8% | 12.8% | 5.0% | 18.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.0% | 9.1% | 11.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.8% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Net Income TTM | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| Market Cap | $2.25B | $1.24B | $761M | $507M | $842M | $954M | $1.06B | $1.09B | $720M | $656M | · | $331M | |
| Enterprise Value | $2.40B | $1.50B | $1.01B | $776M | $1.10B | $1.18B | $1.24B | $1.27B | $899M | $670M | · | · | |
| P/E | 217.2 | -89.3 | -23.8 | -25.2 | -53.6 | -53.7 | 541.8 | -354.8 | 174.1 | 59.8 | 77.0 | 45.3 | |
| P/S | 5.1 | 3.2 | 2.2 | 1.6 | 2.8 | 3.8 | 3.8 | 4.2 | 3.8 | 3.6 | · | 2.3 | |
| P/B | 5.0 | 4.5 | 2.7 | 1.8 | 2.8 | 2.9 | 3.7 | 4.0 | 2.6 | 3.1 | · | 2.2 | |
| P / Tangible Book | 31.9 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 56.4 | 55.8 | 40.4 | -98.4 | -325.9 | 77.1 | 66.8 | 110.5 | 66.7 | 33.2 | · | 40.8 | |
| P / FCF | 2681.7 | 112.4 | 66.8 | -35.8 | -53.7 | 189.2 | 136.3 | 266.6 | 172.7 | 48.5 | · | 87.0 | |
| EV / EBITDA | 42.7 | 23.8 | 35.0 | 27.1 | 34.2 | 51.1 | 35.0 | 46.2 | 50.8 | 22.2 | · | · | |
| EV / FCF | 2860.7 | 136.0 | 88.6 | -54.7 | -70.0 | 234.9 | 159.8 | 309.4 | 215.6 | 49.6 | · | · | |
| EV / Revenue | 5.4 | 3.9 | 2.9 | 2.5 | 3.7 | 4.7 | 4.5 | 4.8 | 4.7 | 3.7 | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | · | 0.99% | |
| Earnings Yield | 0.46% | -1.1% | -4.2% | -4.0% | -1.9% | -1.9% | 0.18% | -0.28% | 0.57% | 1.7% | 1.3% | 2.2% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | · | 45.0% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $3M | $3M |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $126M | $116M | $116M | $113M | $113M | $99M | $97M | $96M | $98M | $97M | $94M | $88M | $89M | $83M | $79M | $77M | |
| Cost of Revenue | $45M | $41M | $43M | $39M | $40M | $35M | $36M | $35M | $35M | $34M | $33M | $32M | $31M | $30M | $29M | $28M | |
| Gross Profit | $81M | $75M | $73M | $74M | $73M | $64M | $62M | $61M | $63M | $63M | $61M | $56M | $58M | $54M | $51M | $49M | |
| R&D Expense | $9M | $9M | $9M | $8M | $7M | $7M | $7M | $7M | $7M | $7M | $8M | $6M | $7M | $7M | $8M | $12M | |
| SG&A Expense | $80M | $61M | $57M | $57M | $58M | $55M | $51M | $50M | $49M | $31M | $50M | $51M | $57M | $50M | $38M | $41M | |
| Operating Expenses | $89M | $70M | $66M | $65M | $65M | $61M | $59M | $57M | $57M | $38M | $58M | $58M | $65M | $58M | $47M | $53M | |
| Operating Income | $-8M | $6M | $11M | $13M | $8M | $2M | $3M | $4M | $7M | $25M | $3M | $-1M | $8M | $-4M | $4M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $8M | · | $7M | $6M | $6M | · | $5M | |
| Interest Income | $367.0K | $205.0K | $311.0K | $240.0K | $68.0K | $144.0K | $374.0K | $366.0K | $353.0K | $374.0K | $398.0K | $339.0K | $265.0K | $75.0K | $61.0K | $40.0K | |
| Other Non-op | $4M | $-286.0K | $1M | $399.0K | $5M | $3M | $-10M | $2M | $-983.0K | $-1M | $2M | $-2M | $-4M | $963.0K | $4M | $-4M | |
| Pretax Income | $-12M | $339.0K | $7M | $7M | $3M | $-2M | $-17M | $-1M | $-2M | $13M | $-591.0K | $-9M | $-3M | $-9M | $3M | $-13M | |
| Income Tax | $2M | $-1M | $4M | $554.0K | $2M | $-2M | $-119.0K | $1M | $-306.0K | $5M | $3M | $382.0K | $725.0K | $5M | $1M | $1M | |
| Net Income | $-14M | $1M | $2M | $7M | $1M | $-505.0K | $-16M | $-2M | $-2M | $8M | $-4M | $-10M | $-3M | $-14M | $2M | $-14M | |
| EPS (Basic) | $-0.28 | $0.03 | $0.06 | $0.14 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| EPS (Diluted) | $-0.28 | $0.03 | $0.06 | $0.13 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| Shares (Basic) | 48,541,000 | 48,074,000 | · | 47,233,000 | 44,296,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 41,290,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| Shares (Diluted) | 48,541,000 | 49,731,000 | · | 48,775,000 | 45,378,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 47,886,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| EBITDA | $-8M | $12M | · | $13M | $8M | $8M | · | $4M | $7M | $31M | · | $-1M | $8M | $2M | · | $-4M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77M | $56M | $65M | $73M | $53M | $38M | $53M | $56M | $55M | $51M | · | $53M | $49M | $31M | · | $38M | |
| Receivables | $98M | $92M | $90M | $88M | $91M | $88M | $79M | $76M | $74M | $74M | · | $64M | $65M | $63M | · | $57M | |
| Inventory | $103M | $98M | $92M | $91M | $87M | $82M | $80M | $84M | $81M | $82M | · | $79M | $78M | $76M | · | $73M | |
| Prepaid Expense | $27M | $45M | $43M | $22M | $25M | $20M | $19M | $19M | $20M | $17M | · | $17M | $19M | $20M | · | $17M | |
| Current Assets | $371M | $358M | $358M | $337M | $319M | $287M | $290M | $288M | $285M | $277M | · | $267M | $264M | $241M | · | $238M | |
| PP&E (Net) | $74M | $68M | $65M | $41M | $40M | $38M | $36M | $38M | $37M | $38M | · | $37M | $38M | $39M | · | $36M | |
| Goodwill | $350M | $252M | $254M | $254M | $254M | $245M | $241M | $249M | $244M | $245M | $247M | $243M | $246M | $246M | $244M | $235M | |
| Intangibles | $149M | $120M | $124M | $126M | $129M | $128M | $128M | $135M | $135M | $138M | · | $143M | $147M | $150M | · | $148M | |
| Other Non-current Assets | $15M | $16M | $15M | $29M | $27M | $25M | $24M | $21M | $14M | $13M | · | $8M | $8M | $8M | · | $7M | |
| Total Assets | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Accounts Payable | $21M | $18M | $16M | $16M | $19M | $12M | $18M | $11M | $12M | $10M | · | $11M | $10M | $9M | · | $11M | |
| Accrued Liabilities | $16M | $17M | $16M | $12M | $11M | $12M | $12M | $16M | $16M | $16M | · | $10M | $10M | $10M | · | $10M | |
| Current Liabilities | $107M | $93M | $102M | $86M | $67M | $52M | $67M | $153M | $51M | $46M | · | $55M | $56M | $44M | · | $46M | |
| Capital Leases | $36M | $34M | $34M | $38M | $39M | $39M | $40M | $41M | $42M | $43M | · | $43M | $40M | $41M | · | $41M | |
| Deferred Tax | $26M | $28M | $24M | $22M | $23M | $22M | $20M | $19M | $22M | $22M | · | $20M | $19M | $24M | · | $34M | |
| Other Non-current Liabilities | $9M | $9M | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $8M | · | $8M | $7M | $7M | · | $7M | |
| Total Liabilities | $626M | $433M | $437M | $419M | $418M | $497M | $513M | $498M | $494M | $489M | · | $503M | $495M | $477M | · | $488M | |
| Long-term Debt | $363M | $215M | $215M | $215M | $216M | $315M | $314M | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Total Debt | $363M | $215M | · | $215M | $216M | $315M | · | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Common Stock | $502.0K | $500.0K | $493.0K | $488.0K | $486.0K | $442.0K | $434.0K | $434.0K | $433.0K | $432.0K | · | $425.0K | $424.0K | $424.0K | · | $418.0K | |
| Retained Earnings | $-64M | $-50M | $-51M | $-54M | $-60M | $-62M | $-61M | $-45M | $-42M | $-40M | · | $-44M | $-34M | $-31M | · | $-19M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | · | $15M | $15M | $15M | · | $15M | |
| AOCI | $-12M | $-12M | $-3M | $-2M | $-3M | $-19M | $-25M | $-10M | $-16M | $-14M | · | $-21M | $-16M | $-18M | · | $-45M | |
| Stockholders' Equity | $446M | $450M | $448M | $439M | $420M | $294M | $276M | $305M | $295M | $295M | $282M | $272M | $283M | $280M | $284M | $255M | |
| Liabilities + Equity | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Shares Outstanding | 50,179,000 | 49,983,000 | 49,330,000 | 48,862,000 | 48,592,000 | 44,190,000 | 43,432,000 | 43,392,000 | · | · | 42,569,000 | 42,537,000 | 42,443,000 | 42,366,000 | 41,830,000 | 41,816,000 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | |
| Stock-based Comp | $8M | $8M | $4M | $6M | $6M | $8M | $3M | $4M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $3M | · | · | · | $6M | · | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Other Non-cash | · | $-15M | · | · | · | $-30M | · | · | · | $-22M | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-1M | $1M | $20M | $22M | $15M | $-17M | $10M | $11M | $6M | $-5M | $11M | $7M | $7M | $-6M | $-217.0K | $4M | |
| CapEx | $11M | $8M | $28M | $5M | $3M | $4M | $1M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Investing Cash Flow | $-129M | $-11M | $-31M | $-5M | $-3M | $-4M | $-11M | $-11M | $-3M | $-4M | $-3M | $-2M | $7M | $-3M | $-3M | $-3M | |
| Debt Issued | · | · | $0 | $0 | $0 | $0 | $-6M | $160M | $160M | $190M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | $0 | · | · | · | $-66.0K | · | · | · | $-182M | · | · | · | · | · | · | |
| Stock Issued | $1M | $1M | $3M | $5M | $278.0K | $4M | $443.0K | $2M | $59.0K | $4M | $488.0K | $886.0K | $0 | $3M | $24.0K | $1M | |
| Net Stock Activity | · | $1M | · | · | · | $4M | · | · | · | $4M | · | · | · | $3M | · | · | |
| Financing Cash Flow | $152M | $463.0K | $2M | $2M | $3M | $4M | $174.0K | $1M | $-181.0K | $737.0K | $-2M | $-909.0K | $2M | $1M | $-859.0K | $252.0K | |
| Net Change in Cash | $22M | $-9M | $-9M | $20M | $16M | $-16M | $-3M | $1M | $4M | $-8M | $5M | $5M | $18M | $-9M | $2M | $-3M | |
| Free Cash Flow | · | $-7M | · | · | · | $-21M | · | · | · | $-9M | · | · | · | $-8M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-14M | · | · | · | $-18M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.0% | 64.8% | · | 65.6% | 64.7% | 64.2% | · | 63.7% | 64.6% | 64.6% | · | 64.0% | 65.1% | 64.5% | · | 63.4% | |
| Operating Margin | -6.7% | 5.0% | · | 11.1% | 7.4% | 2.2% | · | 4.6% | 6.6% | 26.0% | · | -1.4% | 8.6% | -4.6% | · | -5.3% | |
| Net Margin | -10.7% | 1.2% | · | 5.7% | 1.2% | -0.51% | · | -2.4% | -2.2% | 7.7% | · | -11.2% | -3.8% | -16.3% | · | -17.8% | |
| Pretax Margin | -9.3% | 0.29% | · | 6.2% | 3.1% | -2.3% | · | -1.3% | -2.5% | 13.1% | · | -10.7% | -3.0% | -10.7% | · | -16.3% | |
| EBITDA Margin | -6.7% | 10.4% | · | 11.1% | 7.4% | 7.7% | · | 4.6% | 6.6% | 32.0% | · | -1.4% | 8.6% | 2.2% | · | -5.3% | |
| ROA | -1.4% | 0.17% | · | 0.78% | 0.17% | -0.06% | · | -0.29% | -0.27% | 0.98% | · | -1.3% | -0.44% | -1.8% | · | -1.8% | |
| ROE | -3.1% | 0.38% | · | 1.8% | 0.38% | -0.17% | · | -0.79% | -0.73% | 2.6% | · | -3.7% | -1.2% | -4.7% | · | -4.8% | |
| ROIC | -1.2% | 3.6% | · | 1.8% | 0.51% | 0.08% | · | 1.3% | 0.93% | 2.5% | · | -0.22% | 1.7% | -1.0% | · | -0.80% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.9 | · | 3.9 | 4.8 | 5.5 | · | 1.9 | 5.6 | 6.0 | · | 4.9 | 4.7 | 5.5 | · | 5.2 | |
| Quick Ratio | 1.6 | 1.6 | · | 1.9 | 2.2 | 2.4 | · | 0.9 | 2.5 | 2.7 | · | 2.1 | 2.0 | 2.1 | · | 2.1 | |
| Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| LT Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 0.7 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.2 | · | -0.2 | 1.2 | -0.6 | · | -0.9 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.4 | · | 1.4 | 1.5 | 1.4 | · | 1.4 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.88 | $9.01 | · | $8.98 | $8.64 | $6.66 | · | $7.02 | · | · | · | $6.39 | $6.66 | $6.61 | · | $6.10 | |
| Revenue / Share | $2.59 | $2.34 | · | $2.32 | $2.49 | $2.34 | · | $2.29 | $2.35 | $2.03 | · | $2.15 | $2.19 | $2.06 | · | $1.92 | |
| Cash Flow / Share | · | $0.02 | · | · | · | $-0.40 | · | · | · | $-0.11 | · | · | · | $-0.15 | · | · | |
| Cash / Share | $1.54 | $1.12 | · | $1.50 | $1.10 | $0.85 | · | $1.29 | · | · | · | $1.26 | $1.15 | $0.73 | · | $0.90 | |
| EPS (TTM) | $-0.06 | $0.25 | · | $-0.25 | $-0.43 | $-0.51 | · | $-0.02 | $-0.21 | $-0.24 | · | $-0.60 | $-0.70 | $-0.73 | · | $-1.03 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $471M | $459M | · | $423M | $405M | $390M | · | $385M | $377M | $368M | · | $340M | $329M | $320M | · | $314M | |
| Net Income TTM | $-3M | $12M | · | $-9M | $-18M | $-21M | · | $-851.0K | $-8M | $-10M | · | $-25M | $-28M | $-29M | · | $-41M | |
| Market Cap | $1.13B | $1.83B | · | $2.07B | $1.51B | $1.09B | · | $1.16B | · | · | · | $645M | $730M | $555M | · | $579M | |
| Enterprise Value | $1.41B | $1.99B | · | $2.21B | $1.67B | $1.36B | · | $1.41B | · | · | · | $899M | $988M | $832M | · | $849M | |
| P/E | -374.5 | 146.5 | · | -169.4 | -72.3 | -48.2 | · | -1331.0 | -122.1 | -88.2 | · | -25.3 | -24.6 | -17.9 | · | -13.4 | |
| P/S | 2.4 | 4.0 | · | 4.9 | 3.7 | 2.8 | · | 3.0 | · | · | · | 1.9 | 2.2 | 1.7 | · | 1.8 | |
| P/B | 2.5 | 4.1 | · | 4.7 | 3.6 | 3.7 | · | 3.8 | · | · | · | 2.4 | 2.6 | 2.0 | · | 2.3 | |
| P / Tangible Book | · | 23.2 | · | 35.5 | 41.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 1586.1 | · | · | · | -64.1 | · | · | · | · | · | · | · | -90.2 | · | · | |
| EV / Revenue | 3.0 | 4.3 | · | 5.2 | 4.1 | 3.5 | · | 3.7 | · | · | · | 2.6 | 3.0 | 2.6 | · | 2.7 | |
| Dividend Yield | 0.30% | 0.19% | · | 0.16% | 0.23% | 0.31% | · | 0.30% | · | · | · | 0.53% | 0.47% | 0.61% | · | 0.59% | |
| Earnings Yield | -0.27% | 0.68% | · | -0.59% | -1.4% | -2.1% | · | -0.08% | -0.82% | -1.1% | · | -4.0% | -4.1% | -5.6% | · | -7.4% | |
| Annual Payout | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $441M | $389M | $354M | $314M | $299M |
| Bruttogewinnmarge % | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% |
| Betriebsgewinnmarge % | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% |
| Nettoergebnis | $10M | $-13M | $-31M | $-19M | $-15M |
| Verwässerte EPS | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 |
| Liquiditätsgrad | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 |
| Quick Ratio | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $839.0K | $11M | $11M | $-14M | $-16M |
Institutionelle Eigentümer (13F) 212 Einreicher · $1.2B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
212
Gehaltener Wert
$1.2B
Neue Positionen
34
Geschlossene Positionen
65
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 34 (-7 vs. Vorquartal) | 65 (+29 vs. Vorquartal) | 81 (-12 vs. Vorquartal) | 56 (-7 vs. Vorquartal) | +2.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $149.965.153 | 6.674.017 | 12,78% | Aktien |
| VANGUARD GROUP INC | $144.587.760 | 3.170.089 | 12,33% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $71.566.000 | 3.184.974 | 6,10% | Aktien |
| MORGAN STANLEY | $57.477.400 | 2.557.961 | 4,90% | Aktien |
| Juniper Investment Company, LLC | $45.386.816 | 2.019.885 | 3,87% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $45.043.789 | 2.004.619 | 3,84% | Aktien |
| FMR LLC | $44.119.203 | 1.963.471 | 3,76% | Aktien |
| STATE STREET CORP | $41.750.406 | 1.858.051 | 3,56% | Aktien |
| Ophir Asset Management Pty Ltd | $40.446.180 | 1.800.008 | 3,45% | Aktien |
| PERCEPTIVE ADVISORS LLC | $39.036.906 | 1.737.290 | 3,33% | Aktien |
| Conestoga Capital Advisors, LLC | $36.484.539 | 1.623.700 | 3,11% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $28.318.470 | 1.260.279 | 2,41% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $25.043.403 | 1.114.297 | 2,13% | Aktien |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $23.011.325 | 1.024.091 | 1,96% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22.205.281 | 988.219 | 1,89% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $21.300.127 | 947.941 | 1,82% | Aktien |
| CITADEL ADVISORS LLC | $18.596.037 | 827.594 | 1,59% | Aktien |
| YARGER WEALTH STRATEGIES, LLC | $15.278.432 | 634.223 | 1,30% | Aktien |
| ROYCE & ASSOCIATES LP | $14.364.667 | 639.282 | 1,22% | Aktien |
| NORTHERN TRUST CORP | $12.370.454 | 550.532 | 1,05% | Aktien |
| BANK OF AMERICA CORP /DE/ | $11.716.689 | 521.437 | 1,00% | Aktien |
| Qube Research & Technologies Ltd | $10.704.820 | 476.405 | 0,91% | Aktien |
| FRED ALGER MANAGEMENT, LLC | $10.406.104 | 463.111 | 0,89% | Aktien |
| UBS Group AG | $10.210.390 | 454.401 | 0,87% | Aktien |
| TWO SIGMA ADVISERS, LP | $9.974.907 | 218.700 | 0,85% | Aktien |
| Invesco Ltd. | $9.956.839 | 443.117 | 0,85% | Aktien |
| GOLDMAN SACHS GROUP INC | $9.857.903 | 438.714 | 0,84% | Aktien |
| D. E. Shaw & Co., Inc. | $9.846.714 | 438.216 | 0,84% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9.183.579 | 408.704 | 0,78% | Aktien |
| Toroso Investments, LLC | $9.018.146 | 197.723 | 0,77% | Aktien |
| Soleus Capital Management, L.P. | $8.718.360 | 388.000 | 0,74% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $8.702.159 | 387.279 | 0,74% | Aktien |
| Balyasny Asset Management L.P. | $8.584.686 | 382.051 | 0,73% | Aktien |
| First Eagle Investment Management, LLC | $7.787.496 | 346.573 | 0,66% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $6.978.103 | 310.552 | 0,59% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $6.611.371 | 294.231 | 0,56% | Aktien |
| Legal & General Group Plc | $5.826.427 | 259.298 | 0,50% | Aktien |
| WASATCH ADVISORS LP | $5.726.929 | 156.388 | 0,49% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $5.705.178 | 253.902 | 0,49% | Aktien |
| Bank of New York Mellon Corp | $5.671.109 | 252.386 | 0,48% | Aktien |
| Quantinno Capital Management LP | $4.497.191 | 200.142 | 0,38% | Aktien |
| AMERIPRISE FINANCIAL INC | $4.348.978 | 193.546 | 0,37% | Aktien |
| FIFTH THIRD BANCORP | $4.170.912 | 185.621 | 0,36% | Aktien |
| ORBIMED ADVISORS LLC | $3.932.250 | 175.000 | 0,34% | Aktien |
| Corient Private Wealth LP | $3.580.552 | 159.348 | 0,31% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3.324.253 | 90.777 | 0,28% | Aktien |
| Public Sector Pension Investment Board | $3.298.304 | 146.787 | 0,28% | Aktien |
| Parkman Healthcare Partners LLC | $3.121.982 | 138.940 | 0,27% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $2.879.149 | 128.133 | 0,25% | Aktien |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $2.857.263 | 127.159 | 0,24% | Aktien |
Aktivisten & 5%+-Eigentümer 5 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Juniper Targeted Opportunity Fund, L.P., Juniper HF Investors II, LLC, Juniper Targeted Opportunities, L.P., Juniper Targeted Opportunity Investors, LLC, Juniper Multi-Strategy Fund, L.P., Juniper HF Investors, LLC, Juniper Investment Company, LLC, Alexis P. Michas, John A. Bartholdson ×2 Einreichungen | 12. August 2025 | 4,00% | Änderung | · | SEC |
| CryoLife, Inc., CL Falcon, Inc. | 11. Mai 2011 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Michael A. Roth and Brian J. Stark, as joint filers pursuant to Rule 13d-1(k) | 10. Juli 2007 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Dezember 2005 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 18. März 2005 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 49 Insider · 30 Führungskräfte · 15 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| James P Mackin | President & CEO | 19. August 2026 S | 877.275 | 0 | 9 | $-9.722.946 |
| Lance A Berry | EVP, COO, CFO & Treasurer | 14. August 2026 S | 210.112 | 0 | 5 | $-803.205 |
| David Ashley Lee | Executive VP, COO & CFO | 2. März 2023 S | 347.217 | 0 | 0 | $0 |
| Andrew M Green | SVP, Regulatory and Quality | 10. September 2026 S | 40.160 | 0 | 6 | $-1.431.215 |
| Jean F Holloway | SVP, General Counsel | 12. August 2026 S | 184.118 | 0 | 13 | $-2.537.794 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 3. März 2026 S | 60.097 | 0 | 13 | $-3.426.956 |
| John E Davis | Chief Commercial Officer | 3. März 2026 S | 230.794 | 0 | 9 | $-1.745.924 |
| Amy Horton | VP, Chief Accounting Officer | 3. März 2026 S | 139.088 | 0 | 8 | $-870.080 |
| Matthew A Getz | VP, Human Resources | 16. August 2024 S | 34.116 | 0 | 0 | $0 |
| Florian Tyrs | VP, Global Operations | 27. Februar 2024 S | 21.558 | 0 | 0 | $0 |
| Rochelle L. Maney | VP, Quality | 26. Februar 2024 S | 44.518 | 0 | 0 | $0 |
| Robert C Thomson | VP Research & Development | 23. Februar 2024 A | 13.291 | 0 | 0 | $0 |
| Dennis B Maier | SVP, Operations | 6. Juni 2023 S | 34.724 | 0 | 0 | $0 |
| Franz Peter Barthold | VP, Research & Development | 8. November 2022 A | 32.516 | 0 | 0 | $0 |
| Scott B Capps | VP, Clinical Research | 12. März 2021 F | 153.203 | 0 | 0 | $0 |
| James M Mcdermid | SVP, CHRO | 14. März 2019 F | 30.806 | 0 | 0 | $0 |
| Sherry M Saurini | VP, Quality | 14. März 2019 F | 25.084 | 0 | 0 | $0 |
| William Robert Matthews | Senior VP, Operations, Quality | 5. März 2018 F | 39.883 | 0 | 0 | $0 |
| David C Gale | VP, Research & Development | 16. November 2017 M | 77.135 | 0 | 0 | $0 |
| Steven G Anderson | Former Executive Chairman | 9. April 2015 F | 1.271.846 | 0 | 0 | $0 |
| Bruce G. Anderson | VP, US Sales &Global Marketing | 7. März 2015 F | 42.106 | 0 | 0 | $0 |
| FRONK DAVID | VP, Regulatory Affairs | 7. März 2015 F | 110.559 | 0 | 0 | $0 |
| David P. Lang | VP, Int'l Sales & Marketing | 26. Februar 2015 A | 73.441 | 0 | 0 | $0 |
| Jeffrey W Burris | Vice President & Gen. Counsel | 15. August 2014 M | 95.221 | 0 | 0 | $0 |
| Gerald B Seery | Sr. VP, Sales and Marketing | 30. November 2012 S | 71.999 | 0 | 0 | $0 |
| Albert E Heacox | Sr. VP Research and Devl | 31. Dezember 2011 F | 110.144 | 0 | 0 | $0 |
| Philip A Theodore | VP, General Counsel | 4. September 2007 A | 23.100 | 0 | 0 | $0 |
| Sidney B Ashmore | Vice President of Marketing | 18. Januar 2006 M | 42.728 | 0 | 0 | $0 |
| Kirby S Black | Sr. Vice President, R&D | 21. September 2004 M | 55.131 | 0 | 0 | $0 |
| Vander James C Wyk | VP - Product Integrity | 14. September 2004 M | 36.165 | 0 | 0 | $0 |
| Anthony B. Semedo | Direktor | 2. Juni 2026 J | 6.325 | 0 | 0 | $0 |
| Elizabeth A Hoff | Direktor | 18. Mai 2026 A | 34.765 | 0 | 1 | $-189.420 |
| Marna P Borgstrom | Direktor | 18. Mai 2026 A | 56.664 | 0 | 0 | $0 |
| Jon W Salveson | Direktor | 18. Mai 2026 A | 137.416 | 0 | 0 | $0 |
| Jeffrey H Burbank | Direktor | 18. Mai 2026 A | 61.372 | 0 | 0 | $0 |
| Daniel J Bevevino | Direktor | 18. Mai 2026 A | 157.637 | 0 | 0 | $0 |
| Bullock James | Direktor | 18. Mai 2026 A | 76.223 | 0 | 0 | $0 |
| Thomas F Ackerman | Direktor | 18. Mai 2026 A | 157.472 | 0 | 0 | $0 |
| Harvey Morgan | Direktor | 30. August 2021 G | 46.342 | 0 | 0 | $0 |
| Ronald D Mccall | Direktor | 25. August 2021 S | 121.768 | 0 | 0 | $0 |
| Elkins C Ronald | Direktor | 5. September 2018 S | 64.843 | 0 | 0 | $0 |
| James Benson | Direktor | 2. Oktober 2017 S | 54.086 | 0 | 0 | $0 |
| John M Cook | Direktor | 9. Juni 2009 M | 85.000 | 0 | 0 | $0 |
| LACY VIRGINIA C | Direktor | 24. April 2007 S | 255.280 | 0 | 0 | $0 |
| VAN DYNE BRUCE J MD | Direktor | 1. August 2006 A | 12.800 | 0 | 0 | $0 |
| OSS CAPITAL MANAGEMENT | 10%-Eigentümer | 31. Mai 2007 S | 1.918.000 | 0 | 0 | $0 |
| Michael S Simpson | · | 5. März 2021 F | 33.698 | 0 | 0 | $0 |
| Thomas J Bogenschuetz | · | 5. Mai 2020 A | 23.451 | 0 | 0 | $0 |
| Thomas J Lynch | · | 2. November 2004 A | 5.000 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 36 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,64% | 42.246 NS | 31. Juli 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 0,60% | 46.980 SH | 1. Oktober 2026 | Täglich |
| RZG · Invesco Exchange-Traded Fund Trust | 0,42% | 21.951 SH | 1. Oktober 2026 | Täglich |
| EBIT · Harbor ETF Trust | 0,25% | 1.133 NS | 31. Juli 2026 | N-PORT |
| ESSC · Strategy Shares | 0,17% | 2.304 NS | 31. Juli 2026 | N-PORT |
| IHI · iShares Trust | 0,16% | 203.954 SH | 11. September 2026 | Täglich |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,10% | 50.848 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,07% | 429.440 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,06% | 49.054 SH | 19. August 2026 | Täglich |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,05% | 148.966 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,04% | 21.860 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,04% | 14.453 SH | 11. September 2026 | Täglich |
| IWM · iShares Trust | 0,04% | 1.164.969 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,03% | 263.046 SH | 19. August 2026 | Täglich |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,03% | 23.937 SH | 1. Oktober 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 30.932 SH | 30. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,02% | 124.676 NS | 31. Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 20.435 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 495.296 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 127.662 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,01% | 2.287 SH | 11. September 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,01% | 1.400 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 90.038 NS | 31. Juli 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 3.634 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 4.761 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 9.530 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 13.831 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 61.878 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 10.858 SH | 11. September 2026 | Täglich |
| DFAT · Dimensional ETF Trust | 0,00% | 2.692 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.463.340 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.652 SH | 19. August 2026 | Täglich |
| IJR · iShares Trust | · | 2.603.782 SH | 10. September 2026 | Täglich |
| IJT · iShares Trust | · | 403.685 SH | 9. September 2026 | Täglich |
| XJR · iShares Trust | · | 5.899 SH | 2. September 2026 | Täglich |
| ISCB · iShares Trust | · | 2.111 SH | 11. September 2026 | Täglich |
AORT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 14 Analysten
KAUF
Median-Ziel
$42.00
+88,3%
5 35,7%
Starker Kauf
8 57,1%
Kauf
1 7,1%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
8 Analysten · 2026-09-29Mittelwert-Ziel $42.15 +88,9%
← Unter allen Zielen
Aktueller Preis $22.31
Tief$38.00
Mittelwert$42.15
Hoch$48.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| AORT | $2.25B | 217.2 | 13.6% | 2.2% | 2.2% | 64.4% |
| IRMD | $1.24B | 55.6 | 14.4% | 26.8% | 23.8% | 76.8% |
| IART | · | -1.8 | 1.5% | -31.6% | -49.6% | · |
| ENOV | $1.52B | -1.3 | 6.7% | -52.7% | -58.5% | 59.8% |
| BBNX | $1.35B | -16.8 | 53.9% | -73.0% | -24.9% | 55.4% |
| PRCT | $1.77B | -18.3 | 37.2% | -31.0% | -25.4% | 63.7% |
| CBLL | $822M | -15.0 | 36.1% | -60.0% | -32.6% | 87.9% |
| SIBN | $861M | -44.8 | 20.2% | -9.4% | -10.9% | 79.6% |
| VREX | $498M | -7.0 | 4.1% | -8.3% | -14.0% | 34.4% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 7, 2026